News blog

OptiBiotix Health

  • BY: Andrew Hore |
  • POSTED: 17/04/2015 |

OptiBiotix Health says that its research into cholesterol reduction products and novel sugars remains on course.

OptiBiotix is planning to take advantage of the opportunities provided by the human biome.

The University of Reading’s human studies on 50 people with high cholesterol started in January. There are three groups and most of the participants will have passed the halfway stage by the end of April. The study ends in July and results will be available in September.

The research by NIZO into identifying enzymes that produce novel sugars has completed its first phase. It has found that there is high enzyme in a number of Lactobacilli species tested and very high enzyme activity in a second species. Another species has medium activity and this could lead to additional patent filings.

Ten strains have been identified for further testing.

The share price rose 0.63p to 40.13p. Helium has been trimming its stake in recent weeks but the share price remains strong. 

© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds